6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Abdominal Obesity Metabolic Syndrome
University of Sao PauloSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Abdominal Obesity Metabolic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Intralipid University Health Network, Toronto | Phase 4 | BB |
N-Acetyl-L-Cysteine University Health Network, Toronto | Phase 4 | BB |
Als-L1023 Hanmi Pharmaceutical Company Limited | Phase 3 | B |
Eplerenone Maastricht University Medical Center | Phase 4 | B |
MK-0767 Merck Sharp & Dohme LLC | Phase 2 | CCC |
Same molecule, other indications
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →